Biotechnology company Pheno Therapeutics has secured two new patents protecting its selective GPR17 antagonist pipeline.
The move strengthens the company's intellectual property (IP) position as it advances treatments for neurological and neurodegenerative diseases.
The patents cover the company's lead clinical candidate, PTD802, as well as PTD939, its second GPR17 antagonist programme.
The first protects a polymorph (crystalline form) of PTD802, adding to existing composition-of-matter protection licensed exclusively from UCB.
Meanwhile, the second patent covers the composition of matter for PTD939, providing protection as the programme progresses through IND-enabling studies.
Pheno is initially developing PTD939 for amyotrophic lateral sclerosis (ALS).
PTD802 is a small-molecule therapeutic designed to promote remyelination by targeting GPR17, a receptor involved in regulating oligodendrocyte maturation, the cells responsible for producing the myelin sheath that insulates nerve fibres.
The candidate is initially being developed for multiple sclerosis (MS), where damage to myelin contributes to neurological impairment and disease progression.
The programme has already received clinical trial authorisation from the UK's MHRA and IND clearance from the US FDA.
The company is now preparing for a first-in-human study in healthy volunteers to assess safety and tolerability, with commencement targeted for Q4 2026.
Fraser Murray, CEO of Pheno Therapeutics, said: "We are building a strong, layered IP position around GPR17 with two protected assets, one of which is already cleared for clinical study in the UK and US."
The chemistry and development work carried out by the Pheno team has been instrumental in the success of these patent applications, which will now go on to support the long-term value of the pipeline.
"We look forward to providing further updates as we progress PTD802 to a first-in-human trial.”